In the following phase II trial (NCT02677922) for newly diagnosed, IDH2‐mutant AML ineligible for intensive chemotherapy, the addition of enasidenib to azacitidine significantly improved ORR (74 vs. 36%) without adding serious treatment‐related adverse events compared with azacitidine monotherapy.449. This evidence concerns the gene IDH2 and acute myeloid leukemia.